Contract research organizations and boutique biotech groups have developed pomalidomide derivatives into the most widely used plug-and-play CRBN recruiters: the scaffold provides a clean departure point, gram-scale commercial availability and a largely 'greyed' intellectual-property landscape. Stocking a freezer full of pre-functionalized C4- and